Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2225 - Prognostic significance of local immunity factors in esophageal cancer


09 Sep 2017


Poster display session


Oesophageal Cancer


Evgeniy Kolesnikov


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


E.N. Kolesnikov1, O.I. Kit1, E.Y. Zlatnik2, A.L. Bazaev1, A.Y. Maksimov1, I.A. Novikova2, O.N. Selyutina2, E.S. Bondarenko2, V.S. Trifanov1, L.V. Kharin1, P.N. Gabrichidze1, M.A. Kozhushko1, S.S. Mezentsev1, L.Y. Vladimirova3

Author affiliations

  • 1 Department Of Abdominal Oncology, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 2 Laboratory Of Immunophenotyping Of Tumors, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 3 Drug Therapy Department, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU


Abstract 2225


The purpose of the study was to assess possible prognostic significance of local immunity parameters in patients with esophageal cancer.


We studied tissues of tumor, peritumoral zone (PZ) and resection line (RL) obtained from 37 patients (11 women, 24 men aged 46–78 years) during surgical treatment of esophageal cancer with tumors located in the upper (1), mid (16), lower (19) thoracic esophagus and its abdominal part (1 patient). Histological study showed squamous cell carcinoma, keratinizing in 27 and non-keratinizing in 10 patients. Differentiation of tumors was G3, G2 and G1 in 7, 19 and 11 patients, respectively. The follow-up period lasted from 11 to 22 months. 10 patients received postoperative multi-course CF polychemotherapy. Metastases to distant lymph nodes developed in 13 patients, metastases to parenchymal organs in 6 patients; 7 patients died. 16 patients did not show signs of progression during the follow-up period. Subsets of T, B and NK-lymphocytes were determined in homogenates of tissues obtained during surgery using the FACSCantoII flow cytometer (BD) with a panel of antibodies CD45, CD3, CD4, CD8, CD19, CD16/56; levels of T-regs (CD4+CD25+CD127dim) were also assessed. Percentages of lymphocytes were calculated from the total lymphocyte number, T-regs – from the number of CD3+CD4+ cells.


The ratios of percentages of different lymphocyte subsets were compared in presence or absence of the disease progression during a follow-up period. The ratio of T-regs in PZ to the level in tumor in patients with further progression was 0.643±0.3, while in patients without progression it was significantly lower – 0.15±0.033 (p 


The ratios characterizing local immunity (PZ/tumor and PZ/RL for T-regs and RL/tumor for CD3+CD8+ lymphocytes) in patients with esophageal cancer proved to have prognostic significance for progression.

Clinical trial identification

Legal entity responsible for the study

Rostov Research Institute of Oncology




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.